We are monitoring the impact of COVID-19 & Recession alarm on APAC Capecitabine Market Get in touch with us for detailed analysis Know More

Know More

Share on

Asia Pacific Capecitabine Market Research Report - Segmented By Application, Drug Formulation & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2022 to 2027)

Published: January, 2022
ID: 6197
Pages: 145

Asia Pacific Capecitabine Market Size & Growth (2022 to 2027):

The size of the APAC Capecitabine market was valued at USD XX Million in 2022 and is estimated to reach USD XX Million by 2027, to grow at a CAGR of XX% from 2022 to 2027.

The increased demand for capecitabine can be attributed to its antimetabolite action, which interferes with DNA synthesis and reduces the severity of side effects. The market is also projected to be driven by the growing burden of patients diagnosed with cancer and tumors. Capecitabine is an advanced treatment for metastatic breast cancer that the FDA has approved.

Capecitabine is effective and well-tolerated in breast cancer patients when combined with taxane-based chemotherapy drugs like docetaxel (Taxotere) and paclitaxel (taxol). Furthermore, continuous capecitabine research initiatives and a favorable regulatory environment are good indicators for capecitabine medication demand. The market is expected to develop because of increased healthcare expenditure and investment in cancer treatment or assistance programs by governments and private organizations such as Cancer Care and Cancer Suraksha Scheme.

Increased government funding for cancer research, rising prevalence of different types of cancers in the region, including breast cancer and colorectal cancer, rising prevalence of unhealthy lifestyle-induced diseases such as obesity and hypertension, rapid increase in the geriatric population. With high market success in the Asia Pacific, organizations are concentrating on diversifying their product portfolios, lowering costs, increasing user satisfaction, and improving Capecitabine reliability.

The high cost of capecitabine, its side effects, the availability of competitors such as raltitrexed and leucovorin, and government rules governing capecitabine's safety and efficacy hinder market expansion. In addition, anemia, chest discomfort, diarrhea, vomiting, weakness, blood clotting disorders, and cardiac-related concerns such as cardiomyopathy are significant adverse effects of the medicine.

Other common contraindications include kidney disease, DPD deficiency, and pregnancy. As a result, the market for capecitabine is primarily hampered by treatment cessation and a preference for additional therapy.

This research report on the APAC Capecitabine Market has been segmented and sub-segmented into the following categories:

By Application:

  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others

By Drug Formulation:

  • Tablets
  • Capsules

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia Pacific region is expected to grow at a higher rate during the period. Because of major generic pharmaceutical companies in Asia-Pacific and an increase in government efforts and unique communities, the market for capecitabine is expected to grow. In addition, as a result of increased screening procedures and clinical trials in the Asia Pacific region, there is a greater awareness of cancer prevention in general.

The China capecitabine market and India capecitabine market are the dominating regions and are expected to reach the highest CAGR during the forecast period. In addition, the region's research efforts are enhanced by increased collaboration with foreign organizations. Cancer incidence in China continues to rise, owing to environmental deterioration and lifestyle changes brought about by improved living standards. As a result, capecitabine has a bright future in China, and its market will continue to expand. Capecitabine was approved in China to treat advanced breast cancer, colorectal cancer, and other solid tumors. However, colorectal cancer chemotherapy has relied primarily on standard cytotoxic medicines for many years.

Capecitabine, when taken orally, acts immediately in the intestine, resulting in a more significant drug concentration in tumor tissues than in the blood. It also has a variable dose modification system and easy-to-use administration methods. All of this has contributed to the company's market expansion.

KEY MARKET PLAYERS

Top companies dominating in the APAC Capecitabine Market profiled in the report are Novartis AG, Perrigo Company plc, Bristol-Myers Squibb Company, and Avita Medical Limited, Sensus Healthcare, RXi Pharmaceuticals, Inc, Sonoma Pharmaceuticals, Inc, Valeant Pharmaceuticals International, Inc., Revitol Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation.,

1. Introduction                                                                 

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods       

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                       

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 Epidemology                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                    

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

5. Market Segmentation                                                                              

                5.1 Application                                                 

                                5.1.1 Introduction                                           

                                5.1.2 Colon Cancer                                          

                                5.1.3 Rectal Cancer                                         

                                5.1.4 Breast Cancer                                        

                                5.1.5 Gastric Cancer                                       

                                5.1.6 Others                                      

                                5.1.7 Y-o-Y Growth Analysis, By Application                                         

                                5.1.8 Market Attractiveness Analysis, By Application                                       

                                5.1.9 Market Share Analysis, By Application                                        

                5.2 Drug Formulation                                                     

                                5.2.1 Introduction                                           

                                5.2.2 Tablets                                      

                                5.2.3 Capsules                                  

                                5.2.4 Y-o-Y Growth Analysis, By Drug Formulation                                            

                                5.2.5 Market Attractiveness Analysis, By Drug Formulation                                          

                                5.2.6 Market Share Analysis, By Drug Formulation                                            

6. Geographical Analysis                                                                              

                6.1 Introduction                                                               

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

                                                6.1.3.1 By Geographical Area                     

                                                6.1.3.2 By Application                    

                                                6.1.3.3 By Drug Formulation                       

                                6.1.4  Market Attractiveness Analysis                                     

                                                6.1.4.1 By Geographical Area                     

                                                6.1.4.2 By Application                    

                                                6.1.4.3 By Drug Formulation                       

                                6.1.5  Market Share Analysis                                      

                                                6.1.5.1 By Geographical Area                     

                                                6.1.5.2 By Application                    

                                                6.1.5.3 By Drug Formulation                       

                6.2 China                                                             

                6.3 India                                                              

                6.4 Japan                                                            

                6.5 South Korea                                                               

                6.6 Australia                                                      

7. Strategic Analysis                                                                       

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

8. Market Leaders' Analysis                                                                        

                8.1 Novartis AG                                                

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 Sensus Healthcare                                                   

                8.3 RXi Pharmaceuticals Inc.                                                       

                8.4 Sonoma Pharmaceuticals Inc.                                                             

                8.5 Perrigo Company plc                                                              

                8.6 Bristol-Myers Squibb Company                                                         

                8.7 Pacific World Corporation                                                     

                8.8 Valeant Pharmaceuticals International Inc.                                                   

                8.9 Revitol Corporation                                                 

                8.10 Avita Medical Limited.                                                         

9. Competitive Landscape                                                                           

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

10. Market Outlook and Investment Opportunities                                                                         

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  1. Asia Pacific Capecitabine  Market By Application, From 2022 - 2027 ( USD Million )
  2. Asia Pacific Colon Cancer Market By Region, From 2022 - 2027 ( USD Million )
  3. Asia Pacific Rectal Cancer Market By Region, From 2022 - 2027 ( USD Million )
  4. Asia Pacific Breast Cancer Market By Region, From 2022 - 2027 ( USD Million )
  5. Asia Pacific Gastric Cancer Market By Region, From 2022 - 2027 ( USD Million )
  6. Asia Pacific Others Market By Region, From 2022 - 2027 ( USD Million )
  7. Asia Pacific Capecitabine  Market By Drug Formulation, From 2022 - 2027 ( USD Million )
  8. Asia Pacific Tablets Market By Region, From 2022 - 2027 ( USD Million )
  9. Asia Pacific Capsules Market By Region, From 2022 - 2027 ( USD Million )
  10. Japan Capecitabine  Market By Application, From 2022 - 2027 ( USD Million )
  11. Japan Capecitabine  Market By Drug Formulation, From 2022 - 2027 ( USD Million )
  12. China Capecitabine  Market By Application, From 2022 - 2027 ( USD Million )
  13. China Capecitabine  Market By Drug Formulation, From 2022 - 2027 ( USD Million )
  14. India Capecitabine  Market By Application, From 2022 - 2027 ( USD Million )
  15. India Capecitabine  Market By Drug Formulation, From 2022 - 2027 ( USD Million )
  16. Australia Capecitabine  Market By Application, From 2022 - 2027 ( USD Million )
  17. Australia Capecitabine  Market By Drug Formulation, From 2022 - 2027 ( USD Million )
  18. South Korea Capecitabine  Market By Application, From 2022 - 2027 ( USD Million )
  19. South Korea Capecitabine  Market By Drug Formulation, From 2022 - 2027 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3220


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample